Pharmaceuticals Stocks

Pharmaceuticals

LUPIN FY2025

Lupin

Revenue of ₹22,708 Cr in FY2025.

Rev ₹22,708 Cr +13.5% YoY +5.9% 10Y CAGR PE 33.1

Pharmaceuticals

NATCOPHARM FY2025

Natco Pharma

Revenue grew 15.9% to ₹4,784 Cr in FY2025.

Rev ₹4,784 Cr +15.9% YoY +19.2% 10Y CAGR PE 9.2

Pharmaceuticals

NATCAPSUQ FY2025

Natural Capsule

Revenue of ₹169 Cr in FY2025.

Rev ₹169 Cr +8.9% YoY +9.7% 10Y CAGR PE 200.0

Pharmaceuticals

NEULANDLAB FY2025

Neuland

Revenue of ₹1,477 Cr in FY2025.

Rev ₹1,477 Cr -5.2% YoY +12.2% 10Y CAGR PE 91.5

Pharmaceuticals

NOVARTIND FY2025

Novartis

Revenue of ₹356 Cr in FY2025.

Rev ₹356 Cr +6.3% YoY -8.6% 10Y CAGR PE 35.5

Pharmaceuticals

PFIZER FY2026

Pfizer

Revenue of ₹2,520 Cr in FY2026.

Rev ₹2,520 Cr +10.4% YoY +2.2% 10Y CAGR PE 29.3

Pharmaceuticals

PGHL FY2025

Procter & Gamble Health

Revenue declined 19.1% to ₹945 Cr in FY2025.

Rev ₹945 Cr -19.1% YoY +0.8% 11Y CAGR PE 44.3

Pharmaceuticals

RPGLIFE FY2026

RPG Life Sciences Limited

Revenue of ₹708 Cr in FY2026.

Rev ₹708 Cr +8.3% YoY +9.7% 10Y CAGR PE 42.2

Pharmaceuticals

SANOFI FY2025

Sanofi India

Revenue of ₹1,837 Cr in FY2025.

Rev ₹1,837 Cr -8.7% YoY -1.8% 10Y CAGR PE 23.9

Pharmaceuticals

SHILPAMED FY2025

Shilpa Medicare

Revenue of ₹1,286 Cr in FY2025.

Rev ₹1,286 Cr +11.7% YoY +7.7% 10Y CAGR PE 150.8

Pharmaceuticals

STAR FY2025

Strides Arcolab

Turned profitable with net income of ₹3,598 Cr in FY2025.

Rev ₹4,565 Cr +12.7% YoY +14.3% 10Y CAGR PE 2.6

Pharmaceuticals

SUNPHARMA FY2026

Sun Pharma

Revenue of ₹58,462 Cr in FY2026.

Rev ₹58,462 Cr +11.2% YoY +7.5% 10Y CAGR PE 40.6

Pharmaceuticals

SUVEN FY2025

Suven Life

Revenue declined 43.1% to ₹6.66 Cr in FY2025.

Rev ₹6.66 Cr -43.1% YoY -35.3% 10Y CAGR

Pharmaceuticals

TORNTPHARM FY2026

Torrent Pharma

Revenue grew 21.4% to ₹13,980 Cr in FY2026.

Rev ₹13,980 Cr +21.4% YoY +7.7% 10Y CAGR PE 77.6

Pharmaceuticals

VIYASH FY2025

Viyash Scientific

Turned profitable with net income of ₹32.3 Cr in FY2025.

Rev ₹1,551 Cr +13.3% YoY +13.3% 10Y CAGR PE 200.0

Pharmaceuticals

WOCKPHARMA FY2025

Wockhardt

Reported a net loss of ₹57.0 Cr in FY2025.

Rev ₹3,012 Cr +7.6% YoY -3.9% 10Y CAGR

Pharmaceuticals

ZYDUSLIFE FY2026

Zydus Lifesciences

Revenue grew 19.0% to ₹27,658 Cr in FY2026.

Rev ₹27,658 Cr +19.0% YoY +11.1% 10Y CAGR PE 22.9